HLA DSASAB Class II IgG Antibodies with C1q Screen Test
Comprehensive Introduction to HLA Antibody Detection
The HLA DSASAB Class II IgG Antibodies with C1q Screen Test represents a significant advancement in transplant immunology monitoring. This sophisticated diagnostic tool is specifically designed to detect and characterize donor-specific antibodies that target HLA Class II antigens, which play a critical role in transplant rejection processes. The integration of C1q screening provides additional insight into the complement-activating potential of these antibodies, offering clinicians valuable information for managing transplant patients and optimizing treatment strategies.
What This Test Measures and Detects
This comprehensive test evaluates several key immunological parameters:
- HLA Class II IgG Antibodies: Detects immunoglobulin G antibodies specifically targeting HLA Class II antigens including HLA-DR, HLA-DQ, and HLA-DP molecules
- Donor-Specific Antibodies (DSA): Identifies antibodies that are specifically directed against donor HLA antigens
- C1q Binding Capacity: Assesses the ability of detected antibodies to bind complement component C1q, indicating their potential to activate the classical complement pathway
- Antibody Strength and Specificity: Quantifies antibody levels and determines their precise HLA antigen targets
Who Should Consider This Test
This advanced immunological screening is particularly important for:
- Pre-transplant Candidates: Patients awaiting kidney, heart, lung, or other organ transplants to assess immunological risk
- Post-transplant Patients: Individuals experiencing signs of potential rejection including elevated creatinine levels, proteinuria, or graft dysfunction
- Highly Sensitized Patients: Individuals with previous transplants, blood transfusions, or pregnancies who may have developed HLA antibodies
- Patients with Unexplained Graft Dysfunction: When standard monitoring suggests immunological issues
- Recipients with Previous Antibody-Mediated Rejection: For ongoing monitoring and treatment adjustment
Clinical Benefits of HLA Antibody Testing
Undergoing this comprehensive immunological assessment provides numerous advantages:
- Early Rejection Detection: Identifies antibody-mediated rejection before significant organ damage occurs
- Personalized Treatment Planning: Guides immunosuppressive therapy decisions based on individual antibody profiles
- Improved Transplant Outcomes: Helps prevent chronic rejection and extends graft survival
- Risk Stratification: Assesses immunological risk for future transplant candidates
- Therapeutic Monitoring: Evaluates the effectiveness of desensitization protocols and antibody removal treatments
Understanding Your Test Results
Interpreting HLA antibody test results requires specialized expertise, but general guidance includes:
Positive Results Interpretation
- Detected DSA with C1q Positivity: Indicates high-risk antibodies capable of complement activation, requiring aggressive management
- Detected DSA without C1q Binding: Suggests lower-risk antibodies that may still require monitoring and potential intervention
- Increasing Antibody Levels: May indicate developing rejection or inadequate immunosuppression
Negative Results Interpretation
- No Detectable DSA: Generally indicates lower immediate risk for antibody-mediated rejection
- Stable Negative Results: Supports current treatment regimen adequacy
Clinical Correlation
Results should always be interpreted in the context of clinical symptoms, graft function tests, and other laboratory findings. Your transplant team will integrate these results with your overall clinical picture to make informed treatment decisions.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | HLA DSASAB Class II IgG Antibodies with C1q Screen Test |
| Regular Price | $1200 USD |
| Discount Price | $1000 USD |
| Turnaround Time | 10-12 days |
| Sample Type | 2 mL (1 mL min.) serum from 1 SST |
| Sample Handling | Ship refrigerated or frozen |
| Required Documentation | Brief clinical history and HLA typing report of Donor/Donors |
| Testing Methodology | Luminex X-Map Technology |
National Availability and Booking
General Genetics Corporation provides comprehensive HLA antibody testing services across the United States. We have established branches in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our nationwide network ensures accessible, high-quality immunological testing for transplant patients throughout the country.
Take Action for Your Transplant Health
Don’t leave your transplant outcomes to chance. Early detection and monitoring of HLA antibodies can significantly impact your long-term graft survival and quality of life. Our specialized team is ready to assist you with this critical testing.
Book Your HLA Antibody Test Today:
Call our dedicated transplant testing specialists at +1(267) 388-9828 or schedule your appointment through our secure online booking system. Take the proactive step toward optimal transplant management and improved health outcomes.
